Oral SERM, trans isomer of clomiphene

Enclomiphene

Enclomiphene is the trans isomer of clomiphene citrate, an oral SERM. FDA's 2022 presentation gives a half-life of 10 hours and a 2013 trial paper cites about 7 hours; no FDA-approved drug contains it.4,3

Moderate evidenceGet the app

Level after one dose

Enclomiphene after one dose: 50% at ~10 h, 25% at 20 h, 12.5% at 30 h.

Drawn from the half-life in the app's model, ~10 h. The model's figures

Enclomiphene, also written enclomifene, is the trans isomer of clomiphene citrate, a non-steroidal estrogen receptor antagonist.1,2 Clomiphene is a mixture of two diastereoisomers, zuclomiphene (cis) and enclomiphene (trans); Wiehle and colleagues give the proportions as 38% and 62%, and FDA's 2022 presentation says the enclomiphene content under the USP clomiphene monograph is 50 to 70 percent.3,4

The trial papers call the product Androxal, and the registry lists Repros Therapeutics Inc. as sponsor of the 2011 phase IIb trial described below.3,5 A search of PubMed on 16 November 2026 for enclomiphene in the title or summary text returned 82 records, dated from 1977 to 2026.

The app lists enclomiphene as a SERM in its PCT category.

FDA's 2022 presentation describes enclomiphene as a selective estrogen receptor modulator that "acts by blocking the estrogenic suppression of the HPG axis", after which the pituitary secretes more LH and FSH and the testes make more testosterone.4

The British Society for Sexual Medicine's 2026 position statement says that "zuclomiphene is more oestrogenic, enclomiphene is more anti-oestrogenic".7 In 15 men who had taken clomiphene 25 mg daily for at least 6 weeks, Helo and colleagues (Albany Medical College, with three authors from Repros Therapeutics) measured median serum enclomiphene of 2.2 ng/mL and zuclomiphene of 44.0 ng/mL, a median ratio of 20:1.8 FDA's presentation states that the main metabolite appears to be 4 hydroxy enclomiphene and that excretion is mainly in feces.4

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~10 h
Bioavailability
95%
Typical dose
6.25–25 mg/day
Route
Oral
Time to peak
~2 h

The app's half-life is about 10 hours and its time to peak about 2 hours; the table sets sourced figures beside them.

Table 3.1Pharmacokinetics4 rows
ParameterApp's figureFigure in a source
Half-lifeAbout 10 hoursFDA's 2022 presentation: "Oral enclomiphene is rapidly absorbed with a half-life of 10 hours."4 Wiehle and colleagues, 2013, cite about 7 hours ("serum half-life of ∼7 h") as a known value from an earlier reference.3 In 9 women with polycystic ovary disease given clomiphene 50 mg once, a model-dependent half-life of the isomers could not be determined because of "a very flat terminal half-life and the long-tailed residence time".9
Time to peakAbout 2 hoursFDA's 2022 presentation: "Max serum concentration is 2 to 3 hours after intake."4 After a single clomiphene 50 mg dose in the 9 women, the mean tmax of enclomiphene was 3 hours.9
Bioavailability95%None of the sources read reports a bioavailability figure.
Route and excretionOralFDA's 2022 presentation: "Excretion is mainly in feces."4

In the 6-week trial of Wiehle and colleagues, serum enclomiphene in a subset of the study population showed a rapid rise followed by "a loss that was typical of an apparent first order process", the mean AUC 0-24 h at 25 mg was "∼4.5 times and 7.5 times higher" than at 12.5 and 6.25 mg, and "there was also evidence of an accumulation of drug in the serum because serum levels did not return to baseline 24 h after taking the drug".3 The same paper reports that the effects on LH and total testosterone "persisted for at least 1 week after stopping treatment", and its authors write that this persistence "cannot be attributable to the accumulation of enclomiphene citrate".3 FDA's presentation adds that Cmax rose "in a greater than dose proportional manner from 12.5 to 25 milligram, and a less than dose proportional manner from 25 to 50 milligram", and that PK data are limited, including information on dose adjustments for renal or hepatic impairment.4

The curve below is drawn from the app's half-life and time to peak, with the daily schedule used in the 6-week trial.3

Level over 4 days

Interval between doses

Level, as a share of the peak after one 25 mg dose

As studied: every day3.

An illustration from a pharmacokinetic model using a half-life of 10 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Kaminetsky and colleagues, 201310Proof-of-principle, randomised, open-label, active-control, two-center phase IIB; the record carries a Repros Therapeutics copyright line12 men with secondary hypogonadism previously treated with topical testosteroneOral enclomiphene citrate or topical testosterone gel at fixed doses (not stated in the record); 6 monthsAt 6 months total testosterone was 545 ± 268 (gel) and 525 ± 256 (enclomiphene) pg/dL as printed; only the enclomiphene group had higher LH and FSH; sperm counts were raised in 7 of 7 men at 3 months and 6 of 6 at 6 months on enclomiphene, while the gel did not lift counts above 20 million/mL in any of five men at 3 months and raised counts in only "two or five men" at 6 months as printed; testosterone fell back to pretreatment values one month after treatment
Wiehle and colleagues, 20133Randomised, single-blind, two-centre phase II; capsules supplied by Repros, whose staff are among the authors48 men with secondary hypogonadism enrolled, 44 per protocolEnclomiphene 6.25, 12.5 or 25 mg daily, or AndroGel 5 g daily; 6 weeksDay 42 mean total testosterone 604 (SD 160) ng/dL at 25 mg and 500 (SD 278) with gel (P = 0.23); LH rose with enclomiphene and was suppressed with gel; IGF-1 fell with both treatments (P < 0.05), more with enclomiphene in the paper's summary
Wiehle and colleagues, 20146,5Randomised, double-blind, placebo and active controlled, parallel, multicentre phase IIb; sponsor Repros TherapeuticsIntent-to-treat with a later assessment: 26 placebo, 30 Testim, 25 on 12.5 mg, 32 on 25 mgEnclomiphene 12.5 or 25 mg daily, Testim topical testosterone, or placebo; 3 monthsMean change in morning total testosterone: placebo -16.9, Testim +253.7, 12.5 mg +258.5, 25 mg +197.3 ng/dL
Kim and colleagues, 201611Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre phase III studies (ZA-304, ZA-305); the record gives no funding statement or sponsorOverweight men aged 18 to 60 with secondary hypogonadism; group sizes not in the recordTwo enclomiphene doses against AndroGel 1.62%; 16 weeksTotal testosterone rose in all treatment groups; LH and FSH rose with enclomiphene and fell with gel; sperm concentration stayed in the normal range with enclomiphene, with a marked reduction in spermatogenesis on gel
Thomas and colleagues, 202312Retrospective, single institution; one author reports a grant from Empower; the authors list a modest sample, selection and ascertainment bias, and a higher baseline testosterone in the enclomiphene group46 men on enclomiphene and 32 on clomiphene (infertility, abnormal semen or hypogonadism)Enclomiphene 12.5 mg (14 men) or 25 mg (32 men) daily; at least 3 monthsOn enclomiphene, median testosterone 390 to 581 ng/dL (n = 31, p = 0.026), LH 3.1 to 5.5 (n = 20) and FSH 4.4 to 7.4 mIU/mL (n = 17), estradiol 29.5 to 67 pg/mL (n = 18, p = 0.003); on clomiphene testosterone rose 244 to 470 ng/dL (p < 0.001), and the mean change did not differ between drugs (+124.96 against +177.30 ng/dL, p = 0.491); semen volume and concentration did not change significantly with either drug
Saffati and colleagues, 202413Retrospective, single institution, each man his own control, no washout between drugs; funding none66 men who moved from clomiphene to enclomiphene; mean age 38.45; 78% secondary hypogonadismMedian enclomiphene treatment 8.9 monthsMedian testosterone change +166 ng/dL against +98 on clomiphene (P = 0.20); estradiol change -5.92 against +17.50 pg/mL (P = 0.001); any adverse effect in 13.8% against 47% (P = 0.001)
Tienforti and colleagues, 202314Systematic review and meta-analysis; the record gives no funding statementSeven studies, 292 men with obesity-related functional androgen deficiencyClomiphene 12.5 to 50 mg or enclomiphene 12.5 to 25 mg daily; 1.5 to 4 monthsPooled testosterone rise, estimated separately for each drug: 7.50 nmol/L with enclomiphene (95% CI 6.52 to 8.48; I2 = 4%) and 11.56 nmol/L with clomiphene (9.68 to 13.43; I2 = 69%)

Deeper analysis: Wiehle and colleagues, 2014, and registry NCT01270841

Wiehle and colleagues, writing from Repros Therapeutics with Lipshultz of Baylor College of Medicine, reported in Fertility and Sterility in 2014 a phase II trial of oral enclomiphene against 1% topical testosterone gel in men with secondary hypogonadism.6 The record states that "enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel" and that FSH and LH rose with enclomiphene while sperm counts were conserved.6 The registry entry for the same trial lists Repros as sponsor, a primary outcome of change in total morning testosterone at month 3, and 124 men starting across four arms (its enrollment count is 83 actual, and 18 are listed as not qualifying), of whom 16 on placebo, 19 on Testim, 18 on 12.5 mg and 20 on 25 mg completed.5 Three men on 25 mg and one on Testim left for an adverse event.5 Secondary results at month 3 were LH changes of -0.1 (placebo), -2.4 (Testim), +4.8 (12.5 mg) and +6.9 mIU/mL (25 mg), and sperm concentration changes of -19.1, -29.5, +8.2 and -2.8 million/mL in 13, 13, 12 and 19 men with end-of-study assessments.5 In the registry LH fell on Testim and rose on enclomiphene, whereas the record's wording groups LH with T and E2 as "similar" to the gel.6,5 The PubMed record gives no limitations stated by the authors. The registry records a restrictive agreement: investigators must send a proposed publication to the sponsor, which then has 60 days to review it.5

Deeper analysis: Kim and colleagues, 2016, and FDA's summary of the phase III adverse events

Kim, of the University of Tennessee Graduate School of Medicine, with McCullough and Kaminetsky, reported in BJU International in 2016 two phase III studies in overweight men aged 18 to 60 whose early morning testosterone was 300 ng/dL or lower and whose LH was below 9.4 IU/L.11 Serum samples were taken at baseline and after 16 weeks, and the record gives no group sizes, numerical results, funding statement, sponsor or stated limitations.11 FDA's 2022 presentation summarises the same authors' phase III trials as comparing enclomiphene 12.5 mg, or 12.5 mg raised to 25 mg, with topical testosterone, and lists "2 deaths, which investigators considered unlikely to be due to the study drug".4 It adds that a patient in the 25 mg group and one in the testosterone group stopped for high hematocrit or hemoglobin, and a patient in the 25 mg group stopped for high PSA.4 ClinicalTrials.gov record NCT01993225, a randomised phase III of Androxal 12.5 or 25 mg against AndroGel 1.62% and placebo over 16 weeks with 120 men enrolled, lists Repros Therapeutics Inc. as lead sponsor; the sources do not state whether it is the ZA-304 or ZA-305 study.19 FDA's presentation reports that in 2015 Repros announced a complete response from FDA that the design of phase 3 studies was not adequate to demonstrate clinical benefit.4

Deeper analysis: Wiehle and colleagues, 2013

Wiehle and colleagues, from Repros Therapeutics and the Centre Hospitalier Universitaire Vaudois in Lausanne, enrolled men whose total testosterone was under 350 ng/dL and LH under 12 IU/L, and sampled testosterone and LH hourly for 24 hours on day 1 and day 42.3 At week 6 the share of samples under 300 ng/dL was 46% at 6.25 mg, 26% at 12.5 mg, 0% at 25 mg and 16.4% with the gel, although the paper's sentence introducing these figures says a higher percentage of samples were under 300 ng/dL with the gel.3 Samples over 1000 ng/dL were 6% (17 of 305) with the gel, 0% at 6.25 and 12.5 mg and 1% (2 of 272) at 25 mg.3 The authors report that "there was not a temporal association between the peak drug levels and the maximum concentration levels of LH or total testosterone", that the daily testosterone pattern was "interesting, but not conclusive" because it was not dose-dependent, and that "a much larger study would be required" to explore it.3 The paper's conflict of interest line reads "None declared", and no funding statement appears in the text read.3

Deeper analysis: Saffati and colleagues, 2024

Saffati and colleagues at Baylor College of Medicine reported in Translational Andrology and Urology in 2024 that, in 66 men switched from clomiphene to enclomiphene, any adverse effect was recorded in 8 men (13.8%) on enclomiphene against 31 (47%) on clomiphene, including decreased libido in 8.6% against 33.3%, decreased energy in 5.2% against 16.7%, and mood changes in 0 against 9.1%.13 Erectile dysfunction (8.6% on enclomiphene against 18.2% on clomiphene, P = 0.12) and fatigue (6.9% against 18.2%, P = 0.06) did not differ significantly, and the testosterone change was not significantly different (P = 0.20).13 The authors list as limitations the single institution, a relatively small sample, no washout period ("the possibility of carry-over effects"), different reasons for switching, and a baseline that differed because clomiphene was given to men in a hypogonadal state.13 The paper states "Funding: None", and two of its authors report consulting for companies including AbbVie and Endo Pharmaceuticals.13

5

Doses reported in studies and on labels

The app's typical dose is 6.25 to 25 mg/day, which matches the lowest and highest daily doses in the trials below, while FDA's 2022 review covered proposed forms up to 50 mg.3,4 No label doses are listed because FDA's 2022 presentation states that no FDA-approved drug contains enclomiphene as an active ingredient, and EMA refused authorisation of EnCyzix.4,2

Table 5.1Doses reported in studies and on labels3 rows
SourceDoseFrequencyLength
Wiehle and colleagues, 201336.25, 12.5 or 25 mgDaily6 weeks
Wiehle and colleagues, 2014 (registry)512.5 or 25 mgOnce daily3 months
Kim and colleagues, 2016 (as FDA summarises)4,1112.5 mg, or 12.5 mg raised to 25 mgDaily16 weeks

In registry NCT01270841, other adverse events were recorded in 3 of 28 on placebo, 15 of 33 on Testim, 3 of 27 on enclomiphene 12.5 mg and 3 of 33 on 25 mg; the one serious event, hyperglycemia, was on Testim, and decreased sperm concentration was listed in 8 of 33 on Testim and none on enclomiphene.5

FDA's 2022 presentation describes, without naming it, a trial of enclomiphene 12.5 and 25 mg, topical testosterone and placebo, with arms that match registry NCT01270841; at 25 mg the events included inability to climax, loss of sensation during intercourse and gastrointestinal symptoms, "considered possibly related to the study drug", and both patients discontinued. For "another 2014 trial" it lists "mildly increased estradiol and headaches".4 In a safety study of 12.5 mg and 12.5 mg raised to 25 mg, FDA lists serious events including bradycardia, chest pain, TIA, hypotension, atrial flutter, pulmonary embolism and deep vein thrombosis, and non-serious hot flushes, muscle spasms and headaches.4 FDA reports that EMA found the incidence of cardiac and thromboembolic events in the enclomiphene group "slightly increased compared to patients treated with testosterone", and EMA's summary names a risk of venous thromboembolism.4,2 FDA's summary of the EMA review lists headache, hot flushes, nausea and muscle spasm as the most frequent events and blurred vision, muscle spasm, headache and aggression as those leading to discontinuation, and says EMA concluded that safety was not sufficiently demonstrated.4 FDA's conclusion lists "cardiac and thromboembolic events; elevated estradiol; increased PSA; and increased hematocrit, with long-term safety data lacking".4

A 2026 case report describes atrial flutter in a 46-year-old man with a mitral valve repair 20 years earlier and chronic immune thrombocytopenia, first documented shortly after he inadvertently increased his enclomiphene dose, taking 50 mg daily in place of 25 mg; the authors state that "causality cannot be established", rate the association "possible" on the Naranjo scale and note a remote atriotomy with chronic atrial and ventricular remodelling, "a substrate sufficient on its own to sustain macro-reentrant atrial flutter".15 In animals, FDA reports deaths in high-dose dogs related to hepatotoxicity and, from the EMA report, cataracts in nonclinical studies, and adds that EMA said the data did not provide conclusive evidence that enclomiphene caused new or progression of existing cataracts and recommended ocular safety monitoring in a risk management plan.4 The meta-analysis of Tienforti and colleagues, which covers clomiphene and enclomiphene together, reports "no treatment-related unexpected findings regarding safety profile" and states that further long-term studies are warranted "to better clarify the safety profile".14

7

Bloodwork and markers

In Thomas and colleagues' retrospective review, estradiol rose from a median of 29.5 to 67 pg/mL on enclomiphene (n = 18, p = 0.003), and the mean change did not differ significantly from clomiphene (+61.18 against +25.01 pg/mL, p = 0.164). In Saffati and colleagues' review the median estradiol change after switching from clomiphene was -5.92 pg/mL on enclomiphene against +17.50 on clomiphene (P = 0.001).12,13 In Wiehle and colleagues' 2013 trial the paper's summary reports that both transdermal testosterone and enclomiphene decreased IGF-1 (P under 0.05), with greater suppression in the enclomiphene groups, while the discussion says levels fell in the enclomiphene groups but not the gel group and "remained within the normal physiological ranges".3 Median hematocrit in Saffati and colleagues' review was 45.6% at baseline, 45.5% after clomiphene and 47.0% after enclomiphene, and the median change in hematocrit was 0.4 on clomiphene and 0 on enclomiphene (P = 0.85).13

FDA's 2022 presentation states that Repros submitted a new drug application for enclomiphene in fertile men with secondary hypogonadism and that in 2015 Repros announced a complete response from FDA citing inadequate phase 3 design and concerns about study entry criteria, titration and bioanalytical method validation.4 EMA's committee adopted a negative opinion on 25 January 2018 on EnCyzix, intended for hypogonadotropic hypogonadism in men and to be used in overweight men with a BMI of at least 25 kg/m2, on an application from Renable Pharma Limited that presented 4 main studies in 588 patients; its stated concerns were that the studies "did not look at whether EnCyzix would improve symptoms such as bone strength, weight gain, impotence and libido" and a risk of venous thromboembolism, so that "the benefits of EnCyzix did not outweigh its risks".2

On 8 June 2022 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 8 no on whether to place enclomiphene citrate on the section 503A bulks list, which FDA had proposed not to include; "several committee members who voted 'No' noted lack of clinical efficacy evidence"; one member stated that more studies need to be conducted, and a member who voted yes noted that USP has a drug substance monograph for clomiphene citrate.16 Empower Pharmacy presented for the nominators at that meeting, and FDA's list updated 14 May 2026 places Enclomiphene Citrate in category 1, bulk drug substances under evaluation.16,17 FDA's presentation concluded that "it's unclear whether increasing testosterone in secondary hypogonadism confers clinical benefit" and that the enclomiphene trials "did not evaluate improvement in hypogonadal symptoms or quality of life".4 The British Society for Sexual Medicine's 2026 statement says enclomiphene is not approved by FDA or EMA, is unlicensed in the UK, and advises that its use be limited to "experienced clinicians within specialist or research settings"; several of its authors are affiliated with Menwell Limited, which trades as Voy, Manual and H3 Health, and the paper states "The authors have nothing to disclose".7

WADA's 2026 Prohibited List, in effect from 1 January 2026, names clomifene among the examples in S4.2 (anti-estrogenic substances, including SERMs; the examples are introduced as "Including, but not limited to"), a class prohibited at all times in and out of competition whose substances are specified substances. The list text does not contain the name enclomiphene, and it does not say whether enclomiphene falls under S4.2 or under S0, which covers any pharmacological substance not addressed elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use.18

9

Storage and handling

FDA's 2022 presentation states that enclomiphene citrate has no USP monograph, that clomiphene "is stable when stored at room temperature and protected from light", and that enclomiphene is "expected to be stable when stored under similar conditions".4

FDA's presentation lists "long-term safety data lacking" and limited PK data, and EMA's summary says the studies did not look at symptoms such as bone strength, weight gain, impotence and libido.4,2 Earl and Kim, as summarised by FDA, noted that "the effects of zuclomiphene are not fully understood".4

What is the half-life of enclomiphene?

The app lists a half-life of about 10 hours, and FDA's 2022 presentation states a half-life of 10 hours for oral enclomiphene.4 Wiehle and colleagues, 2013, cite about 7 hours as a value from an earlier reference.3

Is enclomiphene FDA approved?

No FDA-approved drug contains enclomiphene as an active ingredient, according to FDA's 2022 advisory committee presentation.4 FDA's list updated 14 May 2026 places it in category 1 of the section 503A bulk drug substances under evaluation.17

Was enclomiphene approved in Europe?

EMA's committee adopted a negative opinion on EnCyzix (enclomifene) on 25 January 2018, and the marketing authorisation was refused.2

Is enclomiphene banned by WADA?

The WADA 2026 Prohibited List text does not contain the name enclomiphene.18 Its class S4.2, anti-estrogenic substances including SERMs, names clomifene in examples introduced as "Including, but not limited to" and is prohibited at all times. The list text does not say whether enclomiphene falls under S4.2 or under S0, the non-approved substances class.18

How long does enclomiphene take to peak?

FDA's 2022 presentation states that maximum serum concentration is 2 to 3 hours after intake, against the app's figure of about 2 hours.4

What did the phase 3 trials of enclomiphene find?

In two 16-week phase III studies in overweight men with secondary hypogonadism, testosterone rose in all treatment groups, LH and FSH rose with enclomiphene and fell with AndroGel 1.62%, and sperm concentration stayed in the normal range with enclomiphene.11 FDA's summary of those trials lists 2 deaths that investigators considered unlikely to be due to the study drug.4

Does enclomiphene change sperm counts?

In Kaminetsky and colleagues' 12-man trial, sperm counts were raised in 7 of 7 men at 3 months and 6 of 6 at 6 months on enclomiphene, while the gel did not lift counts above 20 million/mL in any of five men at 3 months.10 In registry NCT01270841 the mean change in sperm concentration at month 3 was +8.2 million/mL at 12.5 mg (n = 12) and -2.8 at 25 mg (n = 19), against -19.1 on placebo (n = 13) and -29.5 on Testim (n = 13), with standard deviations of 233.1 and 167.0 at the two enclomiphene doses.5 In Thomas and colleagues' retrospective review, semen volume and concentration did not change significantly on either drug.12 FDA's presentation states that FDA does not consider changes in semen parameters alone sufficient to establish efficacy.4

How does enclomiphene compare with clomiphene?

In Saffati and colleagues' retrospective review of 66 men, any adverse effect was recorded in 13.8% on enclomiphene and 47% on clomiphene, while the testosterone change did not differ significantly (+166 against +98 ng/dL, P = 0.20).13 The review's authors list the single institution and the lack of a washout period among its limitations.13

13

References

  1. Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother 2016. PMID 27337642
  2. European Medicines Agency. EnCyzix (enclomifene): refusal of the marketing authorisation, overview and questions and answers. 2018. EMA EnCyzix page
  3. Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int 2013. PMC4155868
  4. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting transcript, 8 June 2022 (enclomiphene citrate presentation by Wolfert and nominator presentations). FDA meeting transcript
  5. ClinicalTrials.gov. NCT01270841: phase IIb study of Androxal (enclomiphene citrate) in men with secondary hypogonadism. Sponsor: Repros Therapeutics Inc. NCT01270841
  6. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril 2014. PMID 25044085
  7. Foster J, Choo L, Patel A, Kirby M, Hackett G. British Society of Sexual Medicine: position statement for the potential use of enclomiphene in the treatment of male hypogonadism. World J Mens Health 2026. PMC13302965
  8. Helo S, Mahon J, Ellen J, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int 2017. PMID 27511863
  9. Ghobadi C, Mirhosseini N, Shiran MR, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol 2009. PMID 19033451
  10. Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med 2013. PMID 23530575
  11. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int 2016. PMID 26496621
  12. Thomas J, Suarez Arbelaez MC, Narasimman M, et al. Efficacy of clomiphene citrate versus enclomiphene citrate for male infertility treatment: a retrospective study. Cureus 2023. PMC10404117
  13. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol 2024. PMC11491226
  14. Tienforti D, Castellini C, Di Giulio F, et al. Selective modulation of estrogen receptor in obese men with androgen deficiency: a systematic review and meta-analysis. Andrology 2023. PMID 36604313
  15. Tariq MN, Abdel Halim AT, Evans JA. Newly detected atrial flutter after enclomiphene dose escalation in a patient with prior mitral valve repair and chronic immune thrombocytopenia: a case report. Cureus 2026. PMID 42741668
  16. US Food and Drug Administration. Final summary minutes, Pharmacy Compounding Advisory Committee meeting, 8 June 2022. FDA meeting minutes
  17. US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, updated 14 May 2026. FDA 503A list
  18. World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA Prohibited List
  19. ClinicalTrials.gov. NCT01993225: phase III study of Androxal (enclomiphene citrate) or AndroGel 1.62% in men with acquired hypogonadotropic hypogonadism. Sponsor: Repros Therapeutics Inc. NCT01993225